Floatz logo

Camonsertib

Advanced Solid Tumor, Adult

Repare TherapeuticsSmall moleculePhase 1/2Dormant
CC
45/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
30/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the Advanced Solid Tumor, Adult cohort.

Asset / SponsorPhaseRating
cgt4255
Cogent Biosciences, Inc.
Phase 1CC
Vobramitamab Duocarmazine
MacroGenics
Phase 1/2C

Same molecule, other indications

Camonsertib is also rated in:

neoplasmDormant
CC
Indicative ·
45 / 100
View asset →
breast cancerDormant
CC
Indicative ·
43 / 100
View asset →
cancerDormant
CC
Indicative ·
42 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →